![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Hubei Biocause Pharmaceutical Co., Ltd. Jingmen City Cn, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Fludarabine phosphate, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2007-311 - Rev 00
This Chemical Type CEP, issued on June 18, 2014, remains in force until May 25, 2018, ensuring its reliability within the pharmaceutical industry.
Substance Number 1781 associated with this CEP further emphasizes